


Remarks

The foregoing amendments to the specification are to insert the priority provisional applications information, for which this application claims benefit. The Abstract has been added as a separate sheet, and should be inserted following the claims in the specification.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,



Thomas J. Digby
Attorney for Applicants
Reg. No. L0242

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346

Date: September 20, 2005